We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+26.89%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$201M
AUM Growth
-$11.2M
(-5.3%)
Cap. Flow
-$54.1M
Cap. Flow
% of AUM
-26.85%
Top 10 Holdings %
Top 10 Hldgs %
49.03%
Holding
61
New
17
Increased
9
Reduced
21
Closed
12
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.06M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$5.61M |
| 3 |
CLLS
Cellectis
CLLS
|
+$4.21M |
| 4 |
Baxter International
BAX
|
+$3.7M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$3.04M |
Top Sells
| 1 |
Iovance Biotherapeutics
IOVA
|
+$11.1M |
| 2 |
Kura Oncology
KURA
|
+$11M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$10.6M |
| 4 |
United Therapeutics
UTHR
|
+$8.89M |
| 5 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$7.42M |
Sector Composition
| 1 | Healthcare | 92.54% |
| 2 | Technology | 4.62% |
| 3 | Energy | 0.39% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares S&P 100 ETF
OEF
$20.5B
| $27.9M | 13.86% |
+195,000
| New | +$26.2M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.3M | 7.1% |
227,212
-192,390
| -46% | -$10.6M |
|
|
RETA
3
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.8M | 6.36% |
82,100
+7,100
| +9% | +$1.08M |
|
|
4
Kura Oncology
KURA
$1.01B
| $11.2M | 5.54% |
685,000
-765,000
| -53% | -$11M |
|
5
Centene
CNC
$32.9B
| $10.1M | 5.04% |
159,700
+17,392
| +12% | +$1.13M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $10.1M | 5.02% |
90,000
-50,000
| -36% | -$5.31M |
|
|
CHNG
7
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $9.3M | 4.62% |
830,100
+270,975
| +48% | +$3.04M |
|
8
Zimmer Biomet
ZBH
$17.4B
| $8.18M | 4.06% |
70,555
-37,595
| -35% | -$4.33M |
|
9
AC Immune
ACIU
$240M
| $7.92M | 3.93% |
1,176,801
+118,104
| +11% | +$858K |
|
10
Cue Biopharma
CUE
$120M
| $7.61M | 3.78% |
10,343
-8,059
| -44% | -$5.84M |
|
11
Cigna
CI
$78.8B
| $7.22M | 3.59% |
38,500
+1,371
| +4% | +$260K |
|
|
12
Bristol-Myers Squibb
BMY
$120B
| $6.94M | 3.44% |
+118,000
| New | +$7.06M |
|
13
Aldeyra Therapeutics
ALDX
$116M
| $6.76M | 3.35% |
1,620,200
-415,140
| -20% | -$1.52M |
|
14
MeiraGTx Holdings
MGTX
$1.16B
| $6.51M | 3.23% |
519,967
-48,381
| -9% | -$674K |
|
15
uniQure
QURE
$2.82B
| $6.45M | 3.2% |
143,129
-102,435
| -42% | -$6.05M |
|
|
16
Iovance Biotherapeutics
IOVA
$2.12B
| $5.9M | 2.93% |
215,000
-338,100
| -61% | -$11.1M |
|
|
ALBO
17
DELISTED
Albireo Pharma Inc
ALBO
| $5.27M | 2.61% |
198,800
-131,607
| -40% | -$3.1M |
|
|
APTO
18
DELISTED
Aptose Biosciences, Inc.
APTO
| $4.94M | 2.45% |
+1,740
| New | +$5.61M |
|
19
Arrowhead Research
ARWR
$10.1B
| $4.93M | 2.45% |
114,100
+9,363
| +9% | +$330K |
|
|
CLLS
20
Cellectis
CLLS
$283M
| $4.92M | 2.44% |
+276,577
| New | +$4.21M |
|
|
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
| $3.95M | 1.96% |
146,346
-17,362
| -11% | -$479K |
|
22
ADMA Biologics
ADMA
$2.01B
| $3.81M | 1.89% |
1,299,300
+56,600
| +5% | +$163K |
|
|
23
Baxter International
BAX
$11.4B
| $3.66M | 1.82% |
+42,500
| New | +$3.7M |
|
|
24
CALL
Bristol-Myers Squibb
BMY
$120B
| $2.94M | 1.46% |
+50,000
| New | +$2.99M |
|
25
Vericel Corp
VCEL
$2.39B
| $2.9M | 1.44% |
+209,897
| New | +$2.84M |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA